# OnCo record gtb-5550 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gtb-5550/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gtb-5550" ;
  schema:name "GTB-5550"@en ;
  schema:alternateName "GTB-5550 TriKE"@en ;
  schema:description "GTB-5550 is a protein from GT Biopharma, given as an injection under the skin, that wakes up natural killer cells and points them at tumour cells carrying the B7-H3 marker. It is in a first trial in several solid tumours."@en ;
  schema:url <https://onco.cc/drugs/gtb-5550/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.gtbiopharma.com/product-pipeline/overview>, <https://clinicaltrials.gov/study/NCT07541573> ;
  onco:status "phase-1" ;
  onco:tag "pipeline" ;
  onco:modality "Tri-specific natural killer cell engager (dual camelid nanobody, subcutaneous)" ;
  onco:technologies <https://onco.cc/technologies/nk-cell-engagers/> ;
  onco:targets <https://onco.cc/targets/b7h3/> ;
  onco:companies <https://onco.cc/companies/gt-biopharma/> .